Neurogene Inc.
NASDAQNeurogene Inc. heads into the week after its August 12 earnings release with analyst targets scattered across a wide range and short interest entrenched near a fifth of the free float. The analyst reaction to earnings landed within hours of the results. Canaccord Genuity's Whitney Ijem kept her Buy rating but trimmed the target from $180 to $166. Guggenheim moved the other way…
Snapshot as of 25 Sept 2026
Neurogene Inc. heads into the week after its August 12 earnings release with analyst targets scattered across a wide range and short interest entrenched near a fifth of the free float. The analyst reaction to earnings…
Neurogene Inc. heads into its May 15 results carrying two contradictory signals: one of the most bullish options postures in the past year sits alongside a short interest level that still commands nearly a quarter of…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NGNE — free to start on ORTEX.
Sign up for free →Open NGNE on ORTEX